Michael G. Aman, PhD

The Ohio State University - Nisonger Center (UCEDD)
OSU Wexner Medical Center/Office of Health Sciences
The Ohio State University
357 McCampbell Hall
1581 Dodd Dr
Columbus, OH 43210
Phone: 614-688-4196
Email: [email protected]
Login to Update Your Profile
Last Updated: January 08, 2020

Michael G. Aman

Specialty Resource Contacts: Psychopharmacotherapy
Project/Program/Clinic Contacts: Clinical Trials
Discipline(s): Psychology
AUCD Council Membership: Council on Research and Evaluation
No Council Membership
Research: Child and adolescent drug research (a) Autistic and related disorders; (b) Intellectual disability (mental retardation) (ADHD and other comorbid conditions); (c) Disruptive behavior disorders (Conduct Disorder and Oppositional Defiant Disorder); and (d) Attention-Deficit/Hyperactivity Disorder.
Instrument development for assessing problem behavior and monitoring effects of treatments such as pharmacological agents and behavior therapy.
Assessment of cognition, especially in relation to medication treatment.
Use and patterns of psychotropic drugs in patient populations.
Psychopharmacology in adults with intellectual disability.
Psychometric assessment of standardized rating scales.
Education: Michael Aman graduated from the University of Auckland (New Zealand) with a Ph.D. in Psychiatry. His Masters (Child and Experimental Psychology) was from the University of Illinois (Champaign), and his Bachelors (Psychology) was from the University of Windsor (Ontario).
Service: Director, O.S.U. Research Unit on Pediatric Psychopharmacology (RUPP).
2003 recipient of the Career Research Scientist Award of the American Academy on Mental retardation.
Author of over 200 scholarly publications.
Co-developer of the Aberrant Behavior Checklist (ABC), an informant rating scale used in over 200 studies, thus far, of individuals with developmental disabilities.
Co-developer of the Nisonger Child Behavior Rating Form (NCBRF), another informant rating form for assessing young people with developmental disabilities.
Co-editor (with Steven Reiss) of Psychotropic Medications and Developmental Disabilities: The International Consensus Handbook.
Co-editor with John Werry (1999) of Practitioner's Guide to Psychoactive Drugs for Children and Adolescents (2nd Ed.). New York: Plenum Press.
Co-author of the Project MED (Medication EDucation) series of booklets for consumers.
Reviewer on several review sections for the NIH.
Editorial review boards (now and/or in the past) for American Journal on Mental Retardation, Clinical Therapeutics, Journal of Child and Adolescent Psychopharmacology, Journal of Intellectual and Developmental Disability, Research in Developmental Disabilities; and Associate Editor, American Journal on Mental Retardation, 1993-1998.
Editorial Board Chair: Aman, M.G., Alvarez, N., Benefield, W., Crismon, M.L., Green, G., King, B.H., Reiss, S., Rojahn, J., & Szymanski, L. (2000), (Editorial Board). American Journal on Mental Retardation, 105, [Issue #3, Special Issue: In A.J. Rush & A. Frances (Eds.)], The Expert Consensus Guideline Series. Treatment of Psychiatric and Behavioral Problems in Mental Retardation, 159-228.
Member of 35 student Masters, Candidacy, and Dissertation committees.